{"id":"W3212313924","doi":"10.1182/blood-2021-146228","title":"Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Ibrutinib; Tolerability; Adverse effect; Internal medicine; Incidence (geometry); Cumulative incidence; Chronic lymphocytic leukemia; Gastroenterology; Surgery; Cohort; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00213731,0.0003878947,0.0008775197,0.0002400134,0.0002907199,0.0004814402,0.0002724306,0.000429521,0.002745341],"category_scores_gemma":[0.001216898,0.0002179268,0.000841541,0.0003160465,0.0003333913,0.0003339317,0.0002051166,0.001006648,0.0002269036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005344755,"about_ca_system_score_gemma":0.0007583405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006156901,"about_ca_topic_score_gemma":0.002279001,"domain_scores_codex":[0.9992641,0.000427609,0.00006569552,0.00007811579,0.00008374361,0.00008083477],"domain_scores_gemma":[0.9990513,0.0003340008,0.0002915847,0.00004753149,0.00005201478,0.0002236114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8320208,0.0103335,0.05765723,0.0008313,0.002988769,0.0002653978,0.0002379036,0.00150553,0.02450913,0.0001392565,0.001582703,0.06792861],"study_design_scores_gemma":[0.3304236,0.422103,0.2266228,0.00008019339,0.003352671,0.0008045572,0.000145231,0.003355986,0.009589307,0.0003146746,0.003155023,0.00005285251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973843,0.001023503,0.0001903631,0.00004769777,0.00001500222,0.0004655033,0.0002960215,0.00001253881,0.0005650662],"genre_scores_gemma":[0.9984965,0.0002318841,0.0001600059,0.00007427416,0.00003820689,0.0003779686,0.0003194097,0.000002934441,0.0002987622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002745341,"threshold_uncertainty_score":0.01130325,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02485270191560354,"score_gpt":0.3096979181604436,"score_spread":0.2848452162448401,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}